Esperanza Therapeutics

Esperanza Therapeutics is a private, Texas-based early-stage biotech focused on the discovery and development of small molecule therapeutics. The company describes itself as combining AI-driven drug design, medicinal chemistry, high-throughput screening, and translational research capabilities to advance novel drug candidates for unmet clinical needs. Its origins are tied to academic research and translational support from the CPRIT Advanced Cancer Therapeutics program, the Gulf Coast Consortia, and NIH GCC-REACH pilot funding. Publicly available information suggests the company is still in the preclinical stage, and it has not publicly disclosed a detailed named pipeline or specific molecular targets on its website.